Sign in or create an account to add this stock to your watchlist.
About Syneos Health (NASDAQ:SYNH)
Syneos Health, Inc. operates as an integrated biopharmaceutical solutions company in North America, Europe, the Middle East, Africa, the Asia-Pacific, and Latin America. It operates through two segments, Clinical Solutions and Commercial Solutions. The Clinical Solutions segment offers various clinical development services spanning Phase I to Phase IV, including full-service global studies, as well as unbundled service offerings, such as clinical monitoring, investigator recruitment, patient recruitment, data management, and study startup to assist customers with drug development process. The Commercial Solutions segment provides commercialization services, including outsourced field selling solutions, medication adherence, communications, and consulting services. Its customers include small, mid-sized, and large companies in the pharmaceutical, biotechnology, and medical device industries. The company was formerly known as INC Research Holdings, Inc. and changed its name to Syneos Health, Inc. in January 2018. Syneos Health, Inc. was incorporated in 2010 and is headquartered in Raleigh, North Carolina.
Industry, Sector and Symbol
Industry Commercial physical research
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:SYNH
CUSIPN/A
Phone919-876-9300
Debt
Debt-to-Equity Ratio1.01
Current Ratio1.09
Quick Ratio1.09
Price-To-Earnings
Trailing P/E Ratio20.82
Forward P/E Ratio17.12
P/E Growth0.98
Sales & Book Value
Annual Sales$2.67 billion
Price / Sales1.55
Cash Flow$3.7792 per share
Price / Cash10.69
Book Value$28.29 per share
Price / Book1.43
Profitability
EPS (Most Recent Fiscal Year)$1.94
Net Income$-138,460,000.00
Net Margins-5.50%
Return on Equity8.79%
Return on Assets3.53%
Miscellaneous
Employees21,000
Outstanding Shares102,780,000
Syneos Health (NASDAQ:SYNH) Frequently Asked Questions
What is Syneos Health's stock symbol?
Syneos Health trades on the NASDAQ under the ticker symbol "SYNH."
How were Syneos Health's earnings last quarter?
Syneos Health (NASDAQ:SYNH) released its quarterly earnings data on Wednesday, May, 9th. The company reported $0.55 earnings per share for the quarter, topping the Zacks' consensus estimate of $0.51 by $0.04. The company had revenue of $761 million for the quarter, compared to analyst estimates of $767.24 million. Syneos Health had a positive return on equity of 8.79% and a negative net margin of 5.50%. The business's revenue for the quarter was up 201.9% compared to the same quarter last year. View Syneos Health's Earnings History.
When is Syneos Health's next earnings date?
What guidance has Syneos Health issued on next quarter's earnings?
Syneos Health issued an update on its FY18 earnings guidance on Wednesday, May, 9th. The company provided earnings per share guidance of $2.52-$2.80 for the period, compared to the Thomson Reuters consensus EPS estimate of $2.63. The company issued revenue guidance of $3.235-$3.340, compared to the consensus revenue estimate of $3.24 billion.
What price target have analysts set for SYNH?
11 analysts have issued 1 year price objectives for Syneos Health's stock. Their forecasts range from $41.00 to $65.00. On average, they expect Syneos Health's stock price to reach $50.7778 in the next twelve months. View Analyst Ratings for Syneos Health.
Who are some of Syneos Health's key competitors?
Some companies that are related to Syneos Health include Incyte (INCY), ICON (ICLR), Exelixis (EXEL), EXACT Sciences (EXAS), PRA Health Sciences (PRAH), Charles River Laboratories (CRL), BTG (BTGGF), Intrexon (XON), Medpace (MEDP), National Research (NRCIB), National Research (NRCIA), Sorrento Therapeutics (SRNE), Pieris Pharmaceuticals (PIRS), Eloxx Pharmaceuticals (ELOX) and Viralytics (VRACY).
Who are Syneos Health's key executives?
Syneos Health's management team includes the folowing people:
- Mr. Alistair MacDonald, CEO & Director (Age 48)
- Dr. Michael Gibertini Ph.D., Pres of Clinical Devel. for Therapeutic Bus. Units (Age 60)
- Mr. Jason M. Meggs, Exec. VP, Interim CFO & Principal Accounting Officer (Age 42)
- Dr. Judith Ng-Cashin, Chief Scientific Officer
- Ms. Rachel Stahler, Chief Information Officer (Age 42)
Has Syneos Health been receiving favorable news coverage?
News articles about SYNH stock have trended somewhat positive recently, Accern Sentiment reports. Accern ranks the sentiment of news coverage by reviewing more than twenty million news and blog sources. Accern ranks coverage of public companies on a scale of negative one to one, with scores nearest to one being the most favorable. Syneos Health earned a media sentiment score of 0.13 on Accern's scale. They also gave headlines about the company an impact score of 47.30 out of 100, indicating that recent news coverage is somewhat unlikely to have an effect on the company's share price in the next few days.
Who are Syneos Health's major shareholders?
Syneos Health's stock is owned by a variety of of institutional and retail investors. Top institutional investors include Lee Thomas H Partners LP (24.25%), BlackRock Inc. (6.81%), Dimensional Fund Advisors LP (1.72%), Redmile Group LLC (1.48%), Cooke & Bieler LP (1.30%) and Northern Trust Corp (1.01%). Company insiders that own Syneos Health stock include Alistair Macdonald, Avista Capital Partners Ii Gp,, Christopher L Gaenzle, D Jamie Macdonald, David F Burgstahler, Gregory S Rush, Michael Gibertini, Robert W Breckon and Teachers Pension Plan Ontario. View Institutional Ownership Trends for Syneos Health.
Which institutional investors are selling Syneos Health stock?
SYNH stock was sold by a variety of institutional investors in the last quarter, including American International Group Inc.. Company insiders that have sold Syneos Health company stock in the last year include Alistair Macdonald, Christopher L Gaenzle and Gregory S Rush. View Insider Buying and Selling for Syneos Health.
Which institutional investors are buying Syneos Health stock?
SYNH stock was acquired by a variety of institutional investors in the last quarter, including Lee Thomas H Partners LP, BlackRock Inc., Dimensional Fund Advisors LP, Redmile Group LLC, Cooke & Bieler LP, Northern Trust Corp, The Manufacturers Life Insurance Company and GW&K Investment Management LLC. View Insider Buying and Selling for Syneos Health.
How do I buy shares of Syneos Health?
Shares of SYNH can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Syneos Health's stock price today?
One share of SYNH stock can currently be purchased for approximately $40.40.
How big of a company is Syneos Health?
Syneos Health has a market capitalization of $4.15 billion and generates $2.67 billion in revenue each year. The company earns $-138,460,000.00 in net income (profit) each year or $1.94 on an earnings per share basis. Syneos Health employs 21,000 workers across the globe.
How can I contact Syneos Health?
Syneos Health's mailing address is 3201 Beechleaf Court Suite 600, Raleigh NC, 27604. The company can be reached via phone at 919-876-9300 or via email at [email protected]
MarketBeat Community Rating for Syneos Health (SYNH)
MarketBeat's community ratings are surveys of what our community members think about Syneos Health and other stocks. Vote "Outperform" if you believe SYNH will outperform the S&P 500 over the long term. Vote "Underperform" if you believe SYNH will underperform the S&P 500 over the long term. You may vote once every thirty days.
Syneos Health (NASDAQ:SYNH) Price Target and Consensus Rating
(How are Consensus Ratings Calculated?) MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
11 Wall Street analysts have issued ratings and price targets for Syneos Health in the last 12 months. Their average twelve-month price target is $50.7778, suggesting that the stock has a possible upside of 25.69%. The high price target for SYNH is $65.00 and the low price target for SYNH is $41.00. There are currently 3 hold ratings and 8 buy ratings for the stock, resulting in a consensus rating of "Buy."
| Today | 30 Days Ago | 90 Days Ago | 180 Days Ago |
| Consensus Rating: | Buy | Buy | Buy | Buy |
| Consensus Rating Score: | 2.73 | 2.73 | 2.60 | 2.50 |
| Ratings Breakdown: | 0 Sell Rating(s)
3 Hold Rating(s)
8 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
3 Hold Rating(s)
8 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
4 Hold Rating(s)
6 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
5 Hold Rating(s)
5 Buy Rating(s)
0 Strong Buy Rating(s) |
| Consensus Price Target: | $50.7778 | $50.7778 | $49.8750 | $56.1250 |
| Price Target Upside: | 25.69% upside | 34.51% upside | 20.76% upside | 55.90% upside |
Syneos Health (NASDAQ:SYNH) Consensus Price Target History
Syneos Health (NASDAQ:SYNH) Analyst Ratings History
Show:
(Data available from 5/21/2016 forward)
Syneos Health (NASDAQ:SYNH) Dividend History by Quarter
| Announced | Period | Amount | Yield | Ex-Dividend Date | Record Date | Payable Date |
|---|
(Data available from 1/1/2013 forward)
Syneos Health (NASDAQ SYNH) Insider Trading and Institutional Ownership History
Insider Ownership Percentage: 0.57%
Syneos Health (NASDAQ SYNH) Insider Trading History
| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Shares Held After Transaction | Details |
|---|
| 1/22/2018 | Christopher L Gaenzle | CAO | Sell | 1,470 | $41.00 | $60,270.00 | |  |
| 9/18/2017 | Alistair Macdonald | CEO | Sell | 2,348 | $54.60 | $128,200.80 | 99,453 | |
| 9/18/2017 | Christopher L Gaenzle | CAO | Sell | 4,682 | $54.56 | $255,449.92 | 60,579 | |
| 9/18/2017 | Gregory S Rush | CFO | Sell | 9,703 | $54.48 | $528,619.44 | 78,593 | |
| 9/1/2017 | Christopher L Gaenzle | CAO | Sell | 42,601 | $58.67 | $2,499,400.67 | 69,557 | |
| 9/1/2017 | Gregory S Rush | CFO | Sell | 88,739 | $58.99 | $5,234,713.61 | 149,301 | |
| 8/30/2017 | Gregory S Rush | CFO | Sell | 41,420 | $58.26 | $2,413,129.20 | 42,793 | |
| 8/17/2017 | Alistair Macdonald | CEO | Sell | 8,828 | $55.65 | $491,278.20 | 110,629 | |
| 7/3/2017 | Alistair Macdonald | CEO | Sell | 10,555 | $58.38 | $616,200.90 | 83,935 | |
| 6/30/2017 | Christopher L Gaenzle | CAO | Sell | 6,873 | $58.32 | $400,833.36 | 47,450 | |
| 5/1/2017 | Alistair Macdonald | CEO | Sell | 9,467 | $45.00 | $426,015.00 | 83,935 | |
| 4/3/2017 | Christopher L Gaenzle | CAO | Sell | 4,733 | $45.70 | $216,298.10 | 53,050 | |
| 3/3/2017 | Alistair Macdonald | CEO | Sell | 8,828 | $45.00 | $397,260.00 | 83,296 | |
| 1/20/2017 | Alistair Macdonald | CEO | Sell | 1,375 | $50.50 | $69,437.50 | 52,854 | |
| 1/20/2017 | Christopher L Gaenzle | CAO | Sell | 1,186 | $50.09 | $59,406.74 | 40,223 | |
| 1/19/2017 | Gregory S Rush | VP | Sell | 2,907 | $50.57 | $147,006.99 | 45,782 | |
| 1/5/2017 | Alistair Macdonald | CEO | Sell | 14,840 | $52.19 | $774,499.60 | 69,069 | |
| 9/30/2016 | Gregory S Rush | VP | Sell | 35,503 | $44.70 | $1,586,984.10 | 82,712 | |
| 9/27/2016 | D. Jamie Macdonald | CEO | Sell | 53,970 | $44.30 | $2,390,871.00 | 62,220 | |
| 9/26/2016 | Robert W Breckon | Director | Sell | 12,197 | $44.16 | $538,619.52 | 15,561 | |
| 9/19/2016 | David F Burgstahler | Director | Buy | 1,000 | $43.19 | $43,190.00 | 36,065 | |
| 9/14/2016 | Christopher L Gaenzle | CAO | Sell | 4,734 | $43.14 | $204,224.76 | 19,252 | |
| 8/17/2016 | Alistair Macdonald | COO | Sell | 8,828 | $43.80 | $386,666.40 | 63,057 | |
| 8/4/2016 | Avista Capital Partners Ii Gp, | Major Shareholder | Sell | 2,554,409 | $42.06 | $107,438,442.54 | | |
| 8/4/2016 | Teachers Pension Plan Ontario | Director | Sell | 2,445,591 | $42.06 | $102,861,557.46 | | |
| 8/2/2016 | D. Jamie Macdonald | CEO | Sell | 31,279 | $43.00 | $1,344,997.00 | 107,488 | |
| 8/1/2016 | Robert W Breckon | Director | Sell | 108 | $42.00 | $4,536.00 | 7,961 | |
| 7/28/2016 | Gregory S Rush | VP | Sell | 4,066 | $45.23 | $183,905.18 | 22,165 | |
| 7/20/2016 | D. Jamie Macdonald | CEO | Sell | 100,593 | $43.00 | $4,325,499.00 | 105,795 | |
| 7/15/2016 | Gregory S Rush | CFO | Sell | 5,917 | $41.50 | $245,555.50 | 24,016 | |
| 7/11/2016 | Alistair Macdonald | COO | Sell | 9,468 | $40.19 | $380,518.92 | 28,144 | |
| 7/11/2016 | Christopher L Gaenzle | CAO | Sell | 21,918 | $40.20 | $881,103.60 | 33,530 | |
| 7/1/2016 | Gregory S Rush | CFO | Sell | 1,358 | $37.97 | $51,563.26 | 19,457 | |
| 7/1/2016 | Robert W Breckon | Director | Sell | 421 | $37.97 | $15,985.37 | 8,069 | |
| 6/15/2016 | Christopher L Gaenzle | CAO | Sell | 7,702 | $40.14 | $309,158.28 | 18,287 | |
| 6/6/2016 | Michael Gibertini | Insider | Sell | 213,966 | $43.11 | $9,224,074.26 | 200,998 | |
| 6/2/2016 | Robert W Breckon | Director | Sell | 11,691 | $43.53 | $508,909.23 | 19,710 | |
| 5/6/2016 | Avista Capital Partners Ii Gp, | Major Shareholder | Sell | 4,087,054 | $45.12 | $184,407,876.48 | | |
| 5/6/2016 | Teachers Pension Plan Ontario | Director | Sell | 3,912,946 | $45.12 | $176,552,123.52 | | |
| 4/18/2016 | James T Ogle | Director | Sell | 114,806 | $50.00 | $5,740,300.00 | 293,192 | |
| 4/12/2016 | D. Jamie Macdonald | CEO | Sell | 94,675 | $48.00 | $4,544,400.00 | 138,398 | |
| 4/1/2016 | Michael Gibertini | Insider | Sell | 9,000 | $40.78 | $367,020.00 | 56,282 | |
| 3/1/2016 | Michael Gibertini | Insider | Sell | 9,000 | $39.85 | $358,650.00 | 56,282 | |
| 2/4/2016 | Robert W. Breckon | Director | Sell | 3,882 | $40.03 | $155,396.46 | 8,432 | |
| 2/1/2016 | Gregory S. Rush | CFO | Sell | 17,752 | $40.27 | $714,873.04 | 20,132 | |
| 2/1/2016 | Michael Gibertini | insider | Sell | 9,000 | $40.57 | $365,130.00 | 47,282 | |
| 1/4/2016 | Michael Gibertini | insider | Sell | 9,000 | $46.83 | $421,470.00 | 36,282 | |
| 12/31/2015 | Alistair Macdonald | COO | Sell | 159,599 | $47.46 | $7,574,568.54 | 8,699 | |
| 12/31/2015 | Christopher L. Gaenzle | CAO | Sell | 9,468 | $48.18 | $456,168.24 | 7,291 | |
| 12/31/2015 | Gregory S. Rush | CFO | Sell | 35,503 | $48.17 | $1,710,179.51 | 8,132 | |
| 12/29/2015 | James T. Ogle | Director | Sell | 9,717 | $50.06 | $486,433.02 | 183,386 | |
| 12/8/2015 | Christopher L. Gaenzle | CAO | Sell | 25,185 | $41.78 | $1,052,229.30 | 7,291 | |
| 12/8/2015 | Gregory S. Rush | CFO | Sell | 81,035 | $45.13 | $3,657,109.55 | 8,132 | |
| 12/7/2015 | Alistair Macdonald | COO | Sell | 42,959 | $44.63 | $1,917,260.17 | 55,681 | |
| 12/7/2015 | Avista Capital Partners Ii Gp, | Major Shareholder | Sell | 4,597,937 | $45.00 | $206,907,165.00 | | |
| 12/7/2015 | Teachers Pension Plan Ontario | Director | Sell | 4,402,063 | $45.00 | $198,092,835.00 | | |
| 12/1/2015 | Michael Gibertini | insider | Sell | 9,000 | $46.52 | $418,680.00 | 36,282 | |
| 11/2/2015 | Michael Gibertini | insider | Sell | 9,000 | $41.70 | $375,300.00 | 36,282 | |
| 9/28/2015 | Alistair Macdonald | COO | Sell | 44,522 | $39.93 | $1,777,763.46 | 55,681 | |
| 9/14/2015 | Gregory S. Rush | CFO | Sell | 32,426 | $45.06 | $1,461,115.56 | 8,132 | |
| 8/31/2015 | Christopher L. Gaenzle | CAO | Sell | 17,421 | $41.16 | $717,048.36 | 7,291 | |
| 8/31/2015 | James T Ogle | Director | Sell | 55,000 | $41.12 | $2,261,600.00 | 183,386 | |
| 8/17/2015 | Avista Capital Partners Ii Gp, | Major Shareholder | Sell | 4,029,168 | $44.00 | $177,283,392.00 | | |
| 8/17/2015 | Teachers Pension Plan Ontario | Director | Sell | 3,857,525 | $44.00 | $169,731,100.00 | | |
| 8/12/2015 | D. Jamie Macdonald | CEO | Sell | 57,021 | $44.00 | $2,508,924.00 | | |
| 8/12/2015 | Robert W Breckon | Director | Sell | 8,381 | $44.00 | $368,764.00 | | |
| 5/14/2015 | Avista Capital Partners Ii Gp, | Major Shareholder | Sell | 6,599,761 | $29.68 | $195,880,906.48 | | |
| 5/14/2015 | Teachers Pension Plan Ontario | Director | Sell | 6,318,607 | $29.68 | $187,536,255.76 | | |
| 5/7/2015 | Gregory S Rush | CFO | Sell | 12,455 | $29.68 | $369,664.40 | | |
| 5/7/2015 | Michael Gibertini | Insider | Sell | 50,000 | $29.68 | $1,484,000.00 | | |
| 5/7/2015 | Robert W Breckon | Director | Sell | 8,226 | $29.68 | $244,147.68 | | |
(Data available from 1/1/2013 forward)
Syneos Health (NASDAQ SYNH) News Headlines
| Source: |
|
Syneos Health (NASDAQ:SYNH) SEC Filings
This page is loading this company's SEC Filings. Please wait...
Syneos Health (NASDAQ:SYNH) Income Statement, Balance Sheet and Cash Flow Statement
Syneos Health (NASDAQ SYNH) Stock Chart for Monday, May, 21, 2018
Loading chart…
